Related Experiment Video
Updated: Nov 27, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
[Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review]
Jing-Yu Hu1, Yue-Ru Ji1, Li Liu2
1Department of Hematology, The Second Affiliated Hospital of Air Force Military Medical University, Xi'an 710038, Shanxi Province, China.
Abstract:
Enhancer of zeste homolog 2(EZH2) is a histone methyltransferase which regulate gene expression through epigenetic machinery. The abnormal expression of EZH2 has been described in many cancer types. With in-depth study, it was found that EZH2 is involved in the occurrence and development in many kinds of malignant hematologic disease which may play a dual role of oncogenes and tumor suppressor genes. In recent years, the emergence of EZH2 inhibitors provide a new option for the future treatment of hematological malignancies. In this review, the expression and clinical significance of EZH2 in various of hematological tumors were summarized briefly.
More Related Videos
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
12:44Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis
Published on: November 11, 2014
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Erythropoiesis
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Regulation of Hematopoietic Stem Cells
Abnormal Proliferation
Master Transcription Regulators